2025-02-19 - Analysis Report
## Vertex Pharmaceuticals Inc. (VRTX) Stock Analysis

**0. Summary Statistics:**

VRTX, Vertex Pharmaceuticals Inc., is a biotechnology company focused on the discovery, development, and commercialization of innovative therapies for serious diseases.  The following analysis summarizes key performance indicators and financial data.


**1. Performance Comparison with S&P 500 (VOO):**

VRTX has significantly outperformed the S&P 500 (VOO) over the analyzed period.  The cumulative return for VRTX is 159.53%, while VOO's is 121.84%. This represents a difference of 37.7 percentage points.  The relative divergence (considering historical min/max fluctuation) is 64.9%, indicating VRTX's performance is in the upper 64.9th percentile compared to the S&P 500's performance over the observed period.  The Alpha values in the provided table further support this outperformance, consistently showing positive values above the benchmark.

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 48.0% | 21.7% | 19.0% | 0.1 | 38.5 |
| 2016-2018  | 66.0% | 11.0% | 47.0% | 0.1 | 42.5 |
| 2017-2019  | 88.0% | 11.0% | 57.0% | 0.6 | 56.2 |
| 2018-2020  | 17.0% | 22.8% | -10.0% | 0.2 | 60.7 |
| 2019-2021  | -9.0% | 22.8% | -80.0% | 0.2 | 56.4 |
| 2020-2022  | 10.0% | 22.8% | 2.0% | 0.2 | 74.2 |
| 2021-2023  | 84.0% | 9.6% | 60.0% | 0.5 | 104.5 |
| 2022-2024  | 64.0% | 13.7% | 31.0% | 0.5 | 103.4 |
| 2023-2025  | 51.0% | 13.7% | -11.0% | 0.5 | 117.9 |


**2. Recent Price Movement:**

* **Closing Price:** $459.0
* **5-Day Moving Average:** $459.99
* **20-Day Moving Average:** $453.75
* **60-Day Moving Average:** $442.95

The price is slightly below the 5-day moving average, suggesting minor short-term downward pressure. However, it's above both the 20-day and 60-day moving averages, indicating a generally positive longer-term trend.


**3. Technical Indicators:**

* **RSI:** 57.09  (Neither overbought nor oversold; neutral)
* **PPO:** -0.13 (Slightly negative, suggesting potential bearish momentum)
* **20-Day Relative Divergence Change:** -5.8% (Short-term downward trend)
* **Expected Return:** 21.2% (Long-term expected outperformance relative to the S&P 500)


**4. Recent Earnings Analysis:**

| Date       | EPS    | Revenue     |
|------------|--------|-------------|
| 2024-11-05 | 4.05   | 2.77 B$     |
| 2024-08-02 | -13.92 | 2.65 B$     |
| 2024-05-07 | 4.26   | 2.69 B$     |
| 2023-11-07 | 4.01   | 2.48 B$     |
| 2024-11-05 | 4.01   | 2.48 B$     | *(Duplicate entry - likely an error)*

Earnings show significant volatility.  The large negative EPS in August 2024 needs further investigation to understand the underlying cause.  Overall revenue appears to be growing steadily.  The duplicated entry suggests data inaccuracies which should be verified.


**5. Financial Information:**

No total revenue or gross profit data is available, limiting a comprehensive financial analysis.  This missing information significantly hinders a complete assessment of the company's financial health.


**6. Overall Analysis:**

VRTX has demonstrated strong historical outperformance against the S&P 500.  However, recent earnings show significant volatility and the lack of key financial data restricts a full evaluation.  While the long-term expected return is positive, the recent price movement and the concerning earnings report in Q2 2024 warrant further investigation.  It's crucial to obtain complete and accurate financial data before making any investment decisions. The volatility in EPS requires deeper analysis to assess the sustainability of future earnings and understand any one-time events that may have impacted those quarters.  Investors should consider conducting additional due diligence before making any investment decisions.
